about
The alpha2beta1 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric moleculeSpatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomicsIdentification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study.BioInfra.Prot: A comprehensive proteomics workflow including data standardization, protein inference, expression analysis and data publication.Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected CellsEvaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients.Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.Quantitative proteome analysis of plasma microparticles for the characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma.Quantitative Secretome Analysis of Activated Jurkat Cells Using Click Chemistry-Based Enrichment of Secreted Glycoproteins.One Sample, One Shot - Evaluation of sample preparation protocols for the mass spectrometric proteome analysis of human bile fluid without extensive fractionation.Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines.Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma.Analysis of disease-associated protein expression using quantitative proteomics—fibulin-5 is expressed in association with hepatic fibrosis.Quantitative Analysis of Proteome Modulations in Alveolar Epithelial Type II Cells in Response to Pulmonary Aspergillus fumigatus Infection.A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation.Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags.Proteome Analysis of a Hepatocyte-Specific BIRC5 (Survivin)-Knockout Mouse Model during Liver RegenerationDirect-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patientsMonoclonal antibodies reveal the alteration of the rhodocetin structure upon α2β1 integrin bindingCalibraCurve: A Tool for Calibration of Targeted MS-Based MeasurementsIntegrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder CancerSystematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFiC19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle
P50
Q27654821-5EEFCC55-9A21-4AAC-87C8-EA6440BE66E5Q30843287-C4881168-BC3A-4A5A-AFB8-5CCDB5E063A0Q34303381-79189C7C-DEA3-481A-9D64-E95CDF050F85Q34609315-6F7A214B-B983-4884-A942-11BF7469FD0BQ36399787-074761D7-7977-4816-A6C1-43DFF15BE10EQ36745088-38E24560-EA1D-4019-9071-118ECD5A571DQ37064540-F273AA60-AEBD-4593-AA7B-5FE7B7A27414Q37707024-D6F70497-25FF-483E-B404-364252BF4C1FQ38375370-908D1D78-FE25-4573-B9C3-AE19DFAF3758Q38386901-17566A1B-95FF-4AAD-BABD-197F7097FB79Q38785494-60D23590-B396-417E-9B2E-80F55324C790Q39108916-85C7B03E-46B0-4DB7-9B5B-1184D4A28C7DQ39259431-626C5CEA-BBDA-45DE-9CDA-DDA67E1B6A60Q40034662-809A55DD-DA52-4DBE-995E-CD8F1BCCECA6Q40253359-31E74398-70AB-4000-A3DC-8C7AF2BD1918Q41163686-71E248D7-B09B-4B93-861C-B5C565657F5BQ41993861-7EBF2D22-4D0F-4E8F-AA67-66E97E6EBEC7Q43415554-F4EB28C8-598D-473F-A966-B3639D81BE4FQ48206638-49896CD1-F4E9-40B7-A7B5-D55FAFC99498Q51574758-8AD2F361-C33C-479D-8D28-A489C2A68691Q51610744-67ED6FED-970C-4394-BF5E-1C522F6EA866Q57273249-024AD73E-27B6-48B8-BC1F-513F9D6D73E6Q59350694-5EF8AF51-2540-4BB2-AB63-90774A5D6CD6Q84579209-040BFDB3-BC88-481B-8D3F-F1E989665B91Q89840249-F4923468-8DE9-4DCD-8E0C-E18F19FD3328Q91630639-2131C81B-2137-4D11-8BFB-4069C2CF6132Q91786957-A4245AC8-90D8-40EF-9C8A-0A8E79B28122Q91958724-85DBAE73-D1FE-4139-960D-A1924AF76541
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thilo Bracht
@ast
Thilo Bracht
@en
Thilo Bracht
@es
Thilo Bracht
@nl
type
label
Thilo Bracht
@ast
Thilo Bracht
@en
Thilo Bracht
@es
Thilo Bracht
@nl
prefLabel
Thilo Bracht
@ast
Thilo Bracht
@en
Thilo Bracht
@es
Thilo Bracht
@nl
P108
P106
P1153
35094949500
P31
P496
0000-0002-1194-6614